Controlled trial of intravenous aminophylline in acute cerebral infarction.
In a double-blind trial intravenous aminophylline was compared with placebo in 79 patients with acute cerebral infarction. Immediate improvement in the neurological evaluation score was significantly more frequent in patients receiving aminophylline (38 per cent) than in those on placebo (15 per cent); only patients with mild or moderately severe strokes responded to the injection. After 3 weeks, however, the treated patients did not fare significantly better than the controls in terms of neurological score and residual disability. Survival rate, length of stay in hospital, and social readaptation were similar in the two groups. It is concluded that intravenous aminophylline in patients with ischaemic strokes can bring about an immediate symptomatic relief, but without appreciably influencing the ultimate recovery.
D000208:Acute Disease; D000368:Aged; D000628:Aminophylline / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply*; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007238:Infarction / Q000188:drug therapy* / Q000401:mortality; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D000628:Aminophylline